HLA-PEPTIDE Targeting Antigen Binding Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutic approaches lack specificity and efficacy in targeting tumor cells expressing specific antigens presented by human leukocyte antigen (HLA) peptides, limiting their effectiveness in cancer treatment.
Innovation Solution
Development of isolated antigen binding proteins (ABPs) that specifically bind to HLA-PEPTIDE targets, including HLA Class I molecules complexed with restricted peptides, allowing for precise targeting of tumor cells by mimicking T-cell receptor interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunotherapeutic approaches are used, then treatment coverage is broad, but specificity and efficacy in targeting tumor cells are insufficient
Solution Approach 1:
The patent applies local quality by designing antigen-binding proteins with highly specific paratopes that recognize particular HLA-PEPTIDE complexes. Each ABP is tailored to bind a specific peptide sequence presented by HLA molecules, enabling precise targeting of tumor cells expressing those specific antigens while maintaining effectiveness across different tumor types through the modular nature of the binding proteins.
2Reliability
If T-cell receptor based therapies are used, then cellular immunity is activated, but recognition of native antigens is limited to processed peptide-MHC complexes
Solution Approach 1:
The patent employs copying by creating antigen-binding proteins that replicate and simplify the T-cell receptor recognition mechanism. These ABPs are designed to mimic TCR paratopes that recognize HLA-PEPTIDE complexes, but as standalone proteins that can be administered therapeutically without requiring intact T cells or complex MHC processing machinery, thus simplifying the overall therapeutic mechanism while maintaining reliable immune activation.
Data Source
AI summary
Provided herein are HLA-PEPTIDE targets and antigen binding proteins that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets as well as identifying one or more antigen binding proteins that bind a given HLA-PEPTIDE target.